4 results about "Clinical trial" patented technology

The invention discloses a wet packing agent for treating rheumatoid bone bi-syndrome and a preparation method thereof. The wet packing agent comprises raw common monkshood mother root, raw arisaema root, clematis root, earthworm, zedoary, Szechuan lovage rhizome and Chinese angelica and is prepared by the percolation method. The wet packing agent can be matched with a dual-force air pressure sealing treatment instrument with the transdermal drug delivery way for drug administration on the focus site, and is characterized by high efficacy, short treatment course, safety and reliability to the rheumatoid bone bi-syndrome; furthermore, clinical trails prove that the total effective rate for patients with lumbar intervertebral disc extrusion accompanied with different degrees of spinal stenosis is 98.5%.

The invention provides a preparation process of a rabies vaccine without antibiotic addition in the whole process from a cytotoxic strain source. A Vero cell pre-master cell bank, a master cell bank,a working cell bank, a CTN-1V strain pre-master seed batch, a master seed batch and a working seed batch are prepared by using a culture medium without antibiotic addition, a bioreactor and a flaky carrier are applied, and through performing pre-culture and perfusion culture on Vero cells, inoculating a working seed batch of rabies viruses, performing washing and exchanging, performing perfusion culture to obtain a virus solution, performing ultrafiltration concentration, performing inactivating, performing purifying, preparing a semi-finished product, performing subpackaging and performing freeze-drying, the rabies virus vaccine is obtained. By optimizing the process of the virus adding course of bioreactor culture, impurity residues in the rabies vaccine are effectively reduced, the residual quantity of bovine serum components, Vero cell DNA and Vero cell host proteins is reduced, compared with other vaccine products on the market, the prepared vaccine product has superiority in clinical trial safety, and the safety of biological products is ensured to the greatest extent.

A complex set of performance related requirements defined initially in a clinical trial agreement are functionally evaluated to determine an action responsive to a successful evaluation. A first message identifying a first event initiated transaction within the performance of a clinical trial provides an identification of an investigator and a first event defined data set. Executable template code blocks, specific to the clinical trial and investigator, are retrieved from a distributed database. The executable template code blocks represent declarative* statements that represent discrete operational and financial requirements derived from the clinical trial agreement corresponding to the clinical trial and investigator. An application is executed to determine whether the first event data evaluates successfully against the executable template code blocks. Successful evaluation generates a second event that provides a second message, including the identification of the investigator, clinical trial, and a second event defined data set to the distributed computer system.